Download Full eBooks in PDF
Progress In Neurotherapeutics And Neuropsychopharmacology Volume 1 2006 Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Progress In Neurotherapeutics And Neuropsychopharmacology Volume 1 2006 book. This book definitely worth reading, it is an incredibly well-written.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 185 pages
File Size : 42,8 Mb
Release : 2012-07-26
Category : Medical
ISBN : 9781107405875
An essential update of clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 299 pages
File Size : 48,6 Mb
Release : 2010-05-13
Category : Psychology
ISBN : 0511666977
Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practicing neurologists as well as clinical and translational neuroscientists.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 298 pages
File Size : 52,5 Mb
Release : 2007-04-12
Category : Medical
ISBN : 052186254X
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Jeffrey L. Cummings
Publisher : Cambridge University Press
Page : 314 pages
File Size : 47,6 Mb
Release : 2008-03-06
Category : Medical
ISBN : 9780521862554
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Author : Theodore A. Stern,Maurizio Fava,Timothy E. Wilens,Jerrold F. Rosenbaum
Publisher : Elsevier Health Sciences
Page : 256 pages
File Size : 53,7 Mb
Release : 2015-04-27
Category : Medical
ISBN : 9780323413237
Put today's best approaches to work for your patients with this practical guide to cutting-edge psychopharmacologic and somatic treatments for psychiatric and neurologic conditions. Edited by Drs. Theodore A. Stern, Maurizio Fava, Timothy E. Wilens, and Jerrold F. Rosenbaum, and comprised of key chapters from the second edition of Stern et al.’s Massachusetts General Hospital Comprehensive Clinical Psychiatry, this user-friendly resource focuses on current psychotropic treatments, electroconvulsive therapy, and neurotherapeutics, making it an ideal quick reference for psychiatrists, psychologists, internists, and nurse practitioners. Stay current with hot topics in the field, including the use of antiepileptic drugs in psychiatry, ADHD medications, and often-overlooked areas such as treatment of pain. Benefit from the authoritative content of the parent text, MGH Comprehensive Clinical Psychiatry, 2nd Edition, now featuring new art, new tables, and key points, and updated to DSM-5 where relevant. Get detailed coverage of antidepressants, antipsychotics, and antianxiety medications, as well as drug interactions, side effects, and treatment adherence. Quickly find the information you need with a user-friendly, highly templated format that features abundant boxed summaries, bulleted points, case histories, algorithms, references, and suggested readings. Test your knowledge of psychopharmacology and neurotherapeutics with interactive, downloadable multiple-choice questions with detailed answers for each chapter.
Author : Arthur James Wells
Publisher : Unknown
Page : 2492 pages
File Size : 46,8 Mb
Release : 2006
Category : Bibliography, National
ISBN : UOM:39015066099238
Author : S. Nassir Ghaemi
Publisher : CRC Press
Page : 363 pages
File Size : 49,6 Mb
Release : 2002-05-06
Category : Medical
ISBN : 9780203909027
This practical reference examines the advantages and disadvantages of polypharmacy in psychiatry, and provides up-to-date clinical guidelines on the appropriate use of combinations of pharmacological therapy in major psychiatric disorders-including multidisciplinary approaches to treatment, such as social work and psychopharmacology, and an examina
Author : Allan Tasman,Jerald Kay,Jeffrey A. Lieberman,Michael B. First,Michelle Riba
Publisher : John Wiley & Sons
Page : 2765 pages
File Size : 51,8 Mb
Release : 2015-03-30
Category : Medical
ISBN : 9781118845479
Now in a new Fourth Edition, Psychiatry remains the leading reference on all aspects of the current practice and latest developments in psychiatry. From an international team of recognised expert editors and contributors, Psychiatry provides a truly comprehensive overview of the entire field of psychiatry in 132 chapters across two volumes. It includes two new sections, on psychosomatic medicine and collaborative care, and on emergency psychiatry, and compares Diagnostic and Statistical Manual (DSM-5) and International Classification of Diseases (ICD10) classifications for every psychiatric disorder. Psychiatry, Fourth Edition is an essential reference for psychiatrists in clinical practice and clinical research, residents in training, and for all those involved in the treatment psychiatric disorders. Includes a a companion website at www.tasmanpsychiatry.com featuring PDFs of each chapter and downloadable images
Author : Anonim
Publisher : Academic Press
Page : 404 pages
File Size : 51,5 Mb
Release : 2020-06-29
Category : Medical
ISBN : 9780128201909
The Advances in Pharmacology series presents a variety of chapters from the best authors in the field. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Author : Patrick D. McGorry,Ian B. Hickie
Publisher : Cambridge University Press
Page : 301 pages
File Size : 44,7 Mb
Release : 2019-08-29
Category : Medical
ISBN : 9781108718844
Clinical staging is a solution to transform psychiatric diagnosis and improve mental health outcomes.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse
Publisher : National Academies Press
Page : 483 pages
File Size : 44,8 Mb
Release : 2017-09-28
Category : Medical
ISBN : 9780309459570
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : National Research Council,Division on Behavioral and Social Sciences and Education,Board on Behavioral, Cognitive, and Sensory Sciences,Division on Engineering and Physical Sciences,Standing Committee for Technology Insight--Gauge, Evaluate, and Review,Committee on Military and Intelligence Methodology for Emergent Neurophysiological and Cognitive/Neural Science Research in the Next Two Decades
Publisher : National Academies Press
Page : 215 pages
File Size : 49,5 Mb
Release : 2008-12-06
Category : Medical
ISBN : 9780309118941
Emerging Cognitive Neuroscience and Related Technologies, from the National Research Council, identifies and explores several specific research areas that have implications for U.S. national security, and should therefore be monitored consistently by the intelligence community. These areas include: neurophysiological advances in detecting and measuring indicators of psychological states and intentions of individuals the development of drugs or technologies that can alter human physical or cognitive abilities advances in real-time brain imaging breakthroughs in high-performance computing and neuronal modeling that could allow researchers to develop systems which mimic functions of the human brain, particularly the ability to organize disparate forms of data. As these fields continue to grow, it will be imperative that the intelligence community be able to identify scientific advances relevant to national security when they occur. To do so will require adequate funding, intelligence analysts with advanced training in science and technology, and increased collaboration with the scientific community, particularly academia. A key tool for the intelligence community, this book will also be a useful resource for the health industry, the military, and others with a vested interest in technologies such as brain imaging and cognitive or physical enhancers.
Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Population Health and Public Health Practice,Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda
Publisher : National Academies Press
Page : 487 pages
File Size : 45,6 Mb
Release : 2017-03-31
Category : Science
ISBN : 9780309453073
Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.
Author : British Medical Association
Publisher : CRC Press
Page : 164 pages
File Size : 51,6 Mb
Release : 1997-11-18
Category : Medical
ISBN : 9057023180
At the last Annual Representative Meeting of the British Medical Association a motion was passed that `certain additional cannabinoids should be legalized for wider medicinal use.'' This report supports this landmark statement by reviewing the scientific evidence for the therapeutic use of cannabinoids and sets the agenda for change. It will be welcomed by those who believe that cannabinoids can be used in medical treatment. The report discusses in a clear and readable form the use and adverse effects of the drug for nausea, multiple sclerosis, pain, epilepsy, glaucoma, and asthma.
Author : Maria Nord
Publisher : Linköping University Electronic Press
Page : 72 pages
File Size : 54,5 Mb
Release : 2019-01-07
Category : Electronic
ISBN : 9789176855577
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.